|
CDKN2B-AS1
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Variants in the long noncoding RNA (lncRNA) gene CDKN2B-AS1 (CDKN2B antisense RNA 1; ANRIL) are genome-wide associated with type 2 diabetes (T2D), atherosclerosis, and several forms of cancer.
|
30108282 |
2019 |
|
CDKN2B-AS1
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate the role of lncRNA cyclin-dependent kinase inhibitor 2B antisense RNA 1 (CDKN2B-AS1) in atherosclerosis via its function in A disintegrin and metalloprotease 10 (ADAM10).
|
30926762 |
2019 |
|
CDKN2B-AS1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of CDKN2BAS, a long noncoding RNA gene expression in gingival epithelial cells and gingival fibroblasts of periodontitis shows a strong correlation between the severity of atherosclerosis and PD.
|
31173806 |
2019 |
|
CDKN2B-AS1
|
0.100 |
Biomarker
|
disease |
BEFREE |
To quantify the expression level of three lncRNAs which are known to be relevant to atherosclerosis (ANRIL, NOS3-AS, and APOA1-AS) in SLE patients and to assess their relationship with atherogenic and inflammatory biomarkers.
|
30128915 |
2018 |
|
CDKN2B-AS1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circular non-coding RNA ANRIL modulates ribosomal RNA maturation and atherosclerosis in humans.
|
27539542 |
2016 |
|
CDKN2B-AS1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our study provides further evidence on the significance of 9p21.3 locus for CAD wherein the risk allele regulate the expression of ANRIL and adjacent tumour suppressor genes which in turn alter smooth muscle proliferation, a fundamental process in atherosclerosis.
|
24452806 |
2014 |
|
CDKN2B-AS1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The large non-coding RNA ANRIL, which is associated with atherosclerosis, periodontitis and several forms of cancer, regulates ADIPOR1, VAMP3 and C11ORF10.
|
23813974 |
2013 |
|
CDKN2B-AS1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B.
|
22178423 |
2012 |
|
CDKN2B-AS1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the implication of ANRIL in the modulation of gene sets directly involved in atherosclerosis.
|
22382030 |
2012 |
|
CDKN2B-AS1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Moreover, expression of ANRIL transcripts was directly correlated with severity of atherosclerosis (EU741058 and NR_003529; P=0.02 and P=0.001, respectively).
|
20056914 |
2010 |
|
CDKN2B-AS1
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
9p21.3 may promote atherosclerosis by regulating expression of ANRIL, which in turn is associated with altered expression of genes controlling cellular proliferation pathways.
|
19592466 |
2009 |